Stefano Del Prato, MD PhD

Stefano Del Prato, MD PhD

Professor of Endocrinology and Metabolism
School of Medicine, University of Pisa
Chief of the Section of Diabetes
University of Pisa, Italy
Clinical Associate Professor of Medicine
University of Texas, San Antonio Health Science Center
San Antonio, Texas, USA

Related Videos

Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL? Video

Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL?

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations? Video

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities? Video

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities?

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities?

What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA? Video

What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?

What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations? Video

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities? Video

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities?

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages—i.e., reduced risk of weight gain and hypoglycemia —and unique therapeutic windows of opportunities?

What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA? Video

What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?

What critical advances in the development of long-acting insulin and GLP-1 RA—and combination approaches using both—are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA? ...